Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Bertin

Showing results (101-110 of 112) with videos related to

Pageof 12
Sort By:
Molecular Cell|December 3, 2014
RIP3 induces apoptosis independent of pronecrotic kinase activityPratyusha Mandal, Scott B Berger, Sirika Pillay, et al.
The European Respiratory Journal|December 22, 2022
RIPK1 kinase-dependent inflammation and cell death contribute to the pathogenesis of COPDHannelore P Van Eeckhoutte, Chantal Donovan, Richard Y Kim, et al.
Journal of Medicinal Chemistry|February 9, 2016
DNA-Encoded Library Screening Identifies Benzo[b][1,4]oxazepin-4-ones as Highly Potent and Monoselective Receptor Interacting Protein 1 Kinase InhibitorsPhilip A Harris, Bryan W King, Deepak Bandyopadhyay, et al.
Journal of Medicinal Chemistry|April 26, 2016
The Identification and Pharmacological Characterization of 6-(tert-Butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a Highly Potent and Selective Inhibitor of RIP2 KinasePamela A Haile, Bartholomew J Votta, Robert W Marquis, et al.
Cancer Cell|November 14, 2018
RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic CancerWei Wang, Jill M Marinis, Allison M Beal, et al.
Journal of Medicinal Chemistry|July 3, 2019
Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[<i>d</i>]thiazol-5-ylamino)-6-(<i>tert</i>-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory DiseasesPamela A Haile, Linda N Casillas, Bartholomew J Votta, et al.
ACS Medicinal Chemistry Letters|June 20, 2020
Correction to Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion ChannelPamela A Haile, Linda N Casillas, Michael J Bury, et al.
ACS Medicinal Chemistry Letters|October 23, 2018
Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion ChannelPamela A Haile, Linda N Casillas, Michael J Bury, et al.
Nature|November 9, 2018
Design of amidobenzimidazole STING receptor agonists with systemic activityJoshi M Ramanjulu, G Scott Pesiridis, Jingsong Yang, et al.
Journal of Medicinal Chemistry|February 3, 2017
Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory DiseasesPhilip A Harris, Scott B Berger, Jae U Jeong, et al.
Pageof 12

Showing results (101-110 of 112) with videos related to

Sort By:
Pageof 12
Molecular Cell|December 3, 2014
RIP3 induces apoptosis independent of pronecrotic kinase activityPratyusha Mandal, Scott B Berger, Sirika Pillay, et al.
The European Respiratory Journal|December 22, 2022
RIPK1 kinase-dependent inflammation and cell death contribute to the pathogenesis of COPDHannelore P Van Eeckhoutte, Chantal Donovan, Richard Y Kim, et al.
Journal of Medicinal Chemistry|February 9, 2016
DNA-Encoded Library Screening Identifies Benzo[b][1,4]oxazepin-4-ones as Highly Potent and Monoselective Receptor Interacting Protein 1 Kinase InhibitorsPhilip A Harris, Bryan W King, Deepak Bandyopadhyay, et al.
Journal of Medicinal Chemistry|April 26, 2016
The Identification and Pharmacological Characterization of 6-(tert-Butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a Highly Potent and Selective Inhibitor of RIP2 KinasePamela A Haile, Bartholomew J Votta, Robert W Marquis, et al.
Cancer Cell|November 14, 2018
RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic CancerWei Wang, Jill M Marinis, Allison M Beal, et al.
Journal of Medicinal Chemistry|July 3, 2019
Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[<i>d</i>]thiazol-5-ylamino)-6-(<i>tert</i>-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory DiseasesPamela A Haile, Linda N Casillas, Bartholomew J Votta, et al.
ACS Medicinal Chemistry Letters|June 20, 2020
Correction to Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion ChannelPamela A Haile, Linda N Casillas, Michael J Bury, et al.
ACS Medicinal Chemistry Letters|October 23, 2018
Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion ChannelPamela A Haile, Linda N Casillas, Michael J Bury, et al.
Nature|November 9, 2018
Design of amidobenzimidazole STING receptor agonists with systemic activityJoshi M Ramanjulu, G Scott Pesiridis, Jingsong Yang, et al.
Journal of Medicinal Chemistry|February 3, 2017
Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory DiseasesPhilip A Harris, Scott B Berger, Jae U Jeong, et al.
Pageof 12